# VOLUME 31 1988

## SUBJECT INDEX


Active avoidance reflex extinction, 515
  adrenocorticotropic hormone
  receptor blockers
Acute administration, 699
  ammonium chloride
  creatinine
  thermoregulatory responses
  urea
Acute exposure, 265
  analgesia
  chronic exposure
  nicotine
  restraint stress
  tolerance development
Acute treatment, 541
  anxiety
  avoidance acquisition
  benzodiazepines
  chronic treatment
  handling habituation
Adrenergic receptor antagonists, 573
  lordosis
  luteinizing hormone-releasing hormone
  sexual experience
$\alpha_2$-Adrenoceptors, 33
  chronic stress
  clonidine
  naltrexone
$\beta$-Adrenoceptors, 807
  experimental diabetes
  tricyclics
Adrenocorticotropic hormone, 515
  active avoidance reflex extinction
  receptor blockers
Aggression
  analgesia, 43
  cats, 791
  feeding, 43
  locomotor activity, 43
  mice, male, 43
  midbrain periaqueductal grey, 791
  naloxone, 791
  opiate agonists, 43
  opiate antagonists, 43
Aggression, shock-induced, 103
  animal depression model
  clomipramine
  neonatal administration
Aging
  cortex, 505
  hamsters, 885
  hippocampus, 885
  hypoactivity, 885
  obesity, 885
  passive-avoidance response, 611
  [$^3$H]-prazosin binding, 505
  serotonin, 885
  temazepam, 611
Alcohol, 649
  behavioral effects
  comparison profiles
  marijuana
  subjective effects
Alcohol intake, 813
  angiotensin II
  Sar-1 Thr-8 angiotensin II
Alcohol preferring/alcohol-nonpreferring rat comparisons, 215
  ethanol
  ethanol aversion
Alpha noradrenergic agonists, 87
  catalepsy
Aluminum, 467
  chronic administration
  oral administration
  passive avoidance
Amfonelic acid, 623
  cocaine
  intravenous self-administration
$\gamma$-Aminobutyric acid, 411
  caudate spindle
  drug comparisons
  taurine
$\gamma$-Aminobutyric acid antagonists, 657
  lumbosacral injection
  penile reflexes
  rats, male
  sexual behavior
Aminooxyacetic acid, 693
  anticonflict effects
  diazepam
  pentobarbital
  phenobarbital
Ammonium chloride, 699
  acute administration
  creatinine
  thermoregulatory responses
  urea
Amnesia, 405
  cholinergic neuronal system
  cycloheximide
  GABAergic neuronal system
Amniotic fluid, 351
  analgesia
  dose-dependent effects
  morphine
  placenta
  tail-flick latency
Amphetamine
  circling behavior, 705
  housing, 59
  intravenous self-administration, 59
  sensitization, 705
d-Amphetamine
  atypical antipsychotics, 519
  baboons, 585
  BALB/cByJ mice, 675
  chronic administration, 675
  concurrent schedule, 227
  fenfluramine, 585
  food intake, 585
  locomotor activity, 675
  methylphenidate, 675
  monetary reinforcement, 227
  social interaction, 227
  stereotypy, 519
  time allocation, 227
Analgesia
  acute exposure, 265
  aggression, 43
  amniotic fluid, 351
  anesthesia, 397
  chronic exposure, 265
  cold water swim, 27
  differential effects, 27, 397
  dose-dependent effects, 351
  feeding, 43
  formalin test, 855
  5-hydroxytryptamine, 855
  intrathecal administration, 27
  locomotor activity, 43
  methysergide, 27
  mice, male, 43
  morphine, 351, 855
  nicotine, 265
  opiate agonists, 43
  opiate antagonists, 43
  opiates, 397
  phentolamine, 27
  placenta, 351
  restraint stress, 265
  tail flick latency, 351, 397
  tolerance development, 265
Anesthesia, 397
  analgesia
  differential effects
  opiates
  tail flick latency
Anesthetic effects, 453
  anticonvulsant effects
  flurazepam
  hypothermic effects
  selective breeding
Angiotensin II
  alcohol intake, 813
  drinking, 493
  intracranial injections, 493
  Sar-1 Thr-8 angiotensin II, 813
  tachykinins, 493
Animal depression model, 103
  aggression, shock-induced
  clomipramine
  neonatal administration
Anorexia, 209
  carbachol
  feeding
  hypothalamus
  norepinephrine
  rats, tumor-bearing
Anorexia cachexia, 69

domperidone
gastric ulceration
pimozide
Anticonflict effects, 693
aminooxyacetic acid
diazepam
pentobarbital
phenobarbital
Anticonvulsant effects
anesthetic effects, 453
benzodiazepine/GABA receptor complex, 751
ethanol, 751
flurazepam, 453
hypothermic effects, 453
RO 15-4513, 751
selective breeding, 453
Anticonvulsants, 153
barrel rotation
intrastriatal injection
quinolinic acid
Antidepressant drugs, 243
intracranial self-administration
long-term administration
Antihistamines, 81
feeding behavior
Antinociception
p-chloroamphetamine, 135
drug interactions, 641
ketanserin, 641
morphine, 641
pirenperone, 641
serotonergic pathways, 135
tail-flick latency, 641
Antiserotonergic properties, 321
yohimbine
Anxiety
acute treatment, 541
avoidance acquisition, 541
benzodiazepine receptor ligands, 761
benzodiazepines, 541
buspirone, 317
chlordiazepoxide, 313
chronic treatment, 541
dopamine transmitters, 317
drug interactions, 761
ethanol, 761
exploration, 761
fluid consumption, 313
handling habituation, 541
locomotor activity, 761
neophobia, 313
stress ulcer, 317
Anxiolytic activity, 959
thigmotaxis
Apomorphine
conditioned avoidance, 291
domperidone, 201
drug comparisons, 201
ethanol, 163
genital grooming, 717
haloperidol, 201
hypomotility, 291
intermittent administration, 871
locomotor activity, 871
luteinizing hormone releasing hormone, 291, 871
motility, 163
penile reflexes, 201
spontaneous motor activity, 291
stereotypy, 871
withdrawal, 163
yawning, 717
Apparatus
mini-osmotic pumps, 627, 633
Morris swim maze, 141
radial arm maze, 467
Atropine, 381
cardiac response
monkeys
parasympathetic activity
pyridostigmine
Attenuation, 909
conditioned taste aversion
cross-attenuation
ethanol
ionizing radiation
lithium chloride
Atypical antipsychotics, 519
d-amphetamine
stereotypy
Aversion, 193
GABAergic blockade
medial hypothalamus
morphine
periaqueductal gray
Avoidance, 337
BM123
spontaneous alternation
Avoidance acquisition, 541
acute treatment
anxiety
benzodiazepines
chronic treatment
handling habituation

Baboons, 585
d-amphetamine
fenfluramine
food intake
BALB/cByJ mice, 675
d-amphetamine
chronic administration
locomotor activity
methylphenidate
Barbital, 179
chronic treatment
cross-tolerance
ethanol
pentobarbital
Barrel rotation, 153
anticonvulsants
intrastriatal injection
quinolinic acid
Behavioral activation, 255
dopamine
neurokinin-$\alpha$
ventral tegmental area
Behavioral dependence, 927
caffeine
interactive effects
monkeys
phencyclidine
Behavioral effects, 649
alcohol
comparison profiles
human studies
marijuana
subjective effects
Behavioral investigation, 9
methamphetamine
PMMA
Benzodiazepine/GABA receptor complex, 751
anticonvulsant effects
ethanol
RO 15-4513
Benzodiazepine receptor
CGS 9896, 249
drug discrimination, 249
drug interactions, 733
ethanol, 733
partial inverse agonist, 733
RO 15-4513, 733
stimulus antagonism, 249
Benzodiazepine receptor ligands, 761
anxiety
drug interactions
ethanol
exploration
locomotor activity
Benzodiazepine responsiveness, 15
cholinergic function
Benzodiazepines, 541
acute treatment
anxiety
avoidance acquisition
chronic treatment
handling habituation
Blood pressure, 387
cardiovascular activity
cocaine
human studies
task performance
BM123, 337
avoidance
spontaneous alternation
Body weight, 533
doves
food intake
growth hormone
prolactin
sex differences
Brain
amygdala, 825
caudate-putamen, 523
cerebral cortex, 839
cingulate cortex, 523, 845
dentate gyrus, 523
dorsal tegmentum, 547
dorsomedial hypothalamus, 825
entorhinal-subicular cortex, 523
frontal cortex, 499
hippocampus, 15, 885
hypothalamus, 209, 523
lateral hypothalamus, 547, 825, 845
lateral ventricle, 169, 175
medial hypothalamus, 193
midbrain periaqueductal grey, 791
midbrain pons, 547
nucleus basalis magnocellularis, 141
paraventricular hypothalamus, 825
periaqueductal gray, 193
preoptic area, 169, 175
preoptic-diagonal band, 523
septum, 825
striatum, 15
thalamus, 523
ventral tegmental area, 255
ventral tegmentum, 547
Brain development, 839
offspring effects
prenatal stress
serotonergic system
Brainstem, 547
cholinergic antagonists
lateral hypothalamus
self-stimulation

ventral tegmentum
Buspirone
anxiety, 317
m-chlorophenylpiperazine, 567
dopamine transmitters, 317
food intake, 567
gepirone, 269
locomotor activity, 567
8-OH-DPAT, 567
rats, wild, 269
strain differences, 567
stress ulcer, 317
taming, 269

Caffeine
behavioral dependence, 927
conditioned taste aversion, 579
drug conditioning, 579
interactive effects, 927
monkeys, 927
phencyclidine, 927
Cannula-mapping, 825
eating
opioid agonists
Carbachol
anorexia, 209
feeding, 209
hypothalamus, 209
lateral ventricle, 169
norepinephrine, 209
oxotremorine, 169
preoptic area, 169
rats, experienced males, 169
rats, tumor-bearing, 209
sexual behavior, 169
Carbohydrate, 773
fat intake
d-fenfluramine
hyperphagia, diet-induced
serotonin
Carbon monoxide, 93
cigarettes
human studies, smokers
Cardiac response, 381
atropine
monkeys
parasympathetic activity
pyridostigmine
Cardiovascular activity, 387
blood pressure
cocaine
human studies
task performance
Cardiovascular effects, 877
cocaine
drug interactions
ethanol
human studies, males
Catalepsy, 87
alpha noradrenergic agonists
Cats
aggression, 791
cholecystokinin, 297
food intake, 297
midbrain periaqueductal grey, 791
naloxone, 791
structure-activity relationship, 297
Caudate spindle
γ-aminobutyric acid, 411
dopamine receptors, 417
drug comparisons, 411
lesions, 6-hydroxydopamine, 417
taurine, 411, 417
Cerebral metabolism, 481
2-deoxyglucose
naloxone
opioid antagonists
CGS 8216, 375
drug interactions
ethanol
Ro 15-1788
Ro 15-4513
schedule-controlled responding
CGS 9896, 249
benzodiazepine receptor
drug discrimination
stimulus antagonism
Charybdotoxin, 187
motor recovery
spinal cord injury
Chloramphenicol, 933
morphine
self-stimulation
Chlordiazepoxide
anxiety, 313
fluid consumption, 313
locomotor activity, 371
naloxone, 371
neophobia, 313
opioid mechanisms, 371
p-Chloroamphetamine, 135
antinociception
serotonergic pathways
m-Chlorophenylpiperazine, 567
buspirone
food intake
locomotor activity
8-OH-DPAT
strain differences
Cholecystokinin, 297
cats
food intake
structure-activity relationship
Cholesterol, 75
cingulotomy
corticosterone
β-endorphin
plasma
stress
triglycerides
Cholinergic antagonists, 547
brainstem
lateral hypothalamus
self-stimulation
ventral tegmentum
Cholinergic function
benzodiazepine responsiveness, 15
selective breeding, 345
serotonergic sensitivity, 345
Cholinergic neuronal system, 405
amnesia
cycloheximide
GABAergic neural system
Chronic administration
aluminum, 467
d-amphetamine, 675
BALB/cByJ mice, 675
locomotor activity, 675
methylphenidate, 675
oral administration, 467
passive avoidance, 467
pentobarbital, 459
pigeon/rat comparisons, 459
secobarbital, 459
tolerance, 459
Chronic exposure, 265
acute exposure
analgesia
nicotine
restraint stress
tolerance development
Chronic stress, 33
$\alpha_2$-adrenoceptors
clonidine
naltrexone
Chronic treatment
acute treatment, 541
anxiety, 541
avoidance acquisition, 541
barbital, 179
benzodiazepines, 541
cross-tolerance, 179
ethanol, 179
handling habituation, 541
pentobarbital, 179
Cigarettes, 93
carbon monoxide
human studies, smokers
Cimetidine, 107
cold-water swims
nonopioid analgesia
opioid analgesia
Cingulotomy, 75
cholesterol
corticosterone
β-endorphin
plasma
stress
triglycerides
Circling behavior, 705
amphetamine
sensitization
Classical conditioning, 605
drug addiction model
lesions, 6-hydroxydopamine
rotational behavior
Clomipramine, 103
aggression, shock-induced
animal depression model
neonatal administration
Clonidine, 33
$\alpha_2$-adrenoceptors
chronic stress
naltrexone
Cocaine
amfonelic acid, 623
blood pressure, 387
cardiovascular activity, 387
cardiovascular effects, 877
computer simulation, 327
dopamine uptake/release, 327
drug interactions, 355, 877
ethanol, 877
human studies, 387
human studies, males, 877
intravenous self-administration, 623
in vivo, 327
task performance, 387
Cold water swim
analgesia, 27
cimetidine, 107
differential effects, 27
intrathecal administration, 27
methysergide, 27
nonopioid analgesia, 107
opioid analgesia, 107
phentolamine, 27
Comparison profiles, 649

alcohol
behavioral effects
human studies
marijuana
subjective effects
Computer simulation, 327
cocaine
dopamine uptake/release
in vivo
Concurrent schedule, 227
d-amphetamine
monetary reinforcement
social interaction
time allocation
Conditioned avoidance, 291
apomorphine
hypomotility
luteinizing hormone releasing hormone
spontaneous motor activity
Conditioned Emotional Response, 949
ethanol
ethanol intake
sucrose-fading procedure
Conditioned place preference, 1
conditioned taste aversion
dopamine agonists
opposing effects
Conditioned taste aversion
attenuation, 909
caffeine, 579
conditioned place preference, 1
cross-attenuation, 909
dopamine agonists, 1
drug conditioning, 579
ethanol, 909
ionizing radiation, 909
lithium chloride, 909
opposing effects, 1
Conflict test, 757
ethanol
reaction time
RO 15-4513
Continuous administration
physostigmine, 627, 633
scopolamine, 633
soman, 633
soman activity, 633
toxicity study, 633
Cortex, 505
aging
[$^3$H]-prazosin binding
Corticosterone, 75
cholesterol
cingulotomy
$\beta$-endorphin
plasma
stress
triglycerides
Creatinine, 699
acute administration
ammonium chloride
thermoregulatory responses
urea
Cross-attenuation, 909
attenuation
conditioned taste aversion
ethanol
ionizing radiation
lithium chloride
Cross-tolerance, 179
barbital
chronic treatment
ethanol
pentobarbital
Current intensity, 845
performance
pimozide
reward
self-stimulation
Cycloheximide, 405
amnesia
cholinergic neuronal system
GABAergic neuronal system

Delayed matching-to-sample, 953
differential effects
neuroleptics
pigeons
2-Deoxyglucose, 481
cerebral metabolism
naloxone
opioid antagonists
[D-Arg$^2$]-Dermorphin, 439
drug/peptide comparisons
morphine
route of administration
Diazepam
aminooxyacetic acid, 693
anticonflict effects, 693
drug interactions, 597
ethanol, 597
instrumental behaviors, 597
pentobarbital, 597, 693
phenobarbital, 693
Ro 15-1788, 597
Ro 15-4513, 597
Diet selection, 721
phenylpropanolamine
Differential effects
analgesia, 27, 397
anesthesia, 397
cold water swim, 27
delayed matching-to-sample, 953
intrathecal administration, 27
methysergide, 27
neuroleptics, 953
opiates, 397
phentolamine, 27
pigeons, 953
tail flick latency, 397
Discrimination studies, 279
N-methyl-D-aspartate
phencyclidine
DNA development, 365
delta-9-tetrahydrocannabinol
offspring lethality
postnatal brain growth
prenatal exposure
protein development
RNA development
Domperidone
anorexia cachexia, 69
apomorphine, 201
drug comparisons, 201
gastric ulceration, 69
haloperidol, 201
penile reflexes, 201
pimozide, 69
Dopamine, 255
behavioral activation
neurokinin-$\alpha$
ventral tegmental area

Dopamine agonists, 1
conditioned place preference
conditioned taste aversion
opposing effects
Dopamine mechanisms, 593
drug interaction
exploratory behavior
GABA mechanisms
Dopamine receptors, 417
caudate spindle
lesions, 6-hydroxydopamine
taurine
Dopaminergic supersensitivity, 941
head-twitch response
hypermotility
neuroleptics
stereotyped behavior
Dopamine transmitters, 317
anxiety
buspirone
stress ulcer
Dopamine uptake/release, 327
cocaine
computer simulation
in vivo
Dose-dependent effects, 351
amniotic fluid
analgesia
morphine
placenta
tail-flick latency
Doves, 533
body weight
food intake
growth hormone
prolactin
sex differences
Drinking, 493
angiotensin II
intracranial injections
tachykinins
Drug
alcohol, 541, 649
alprazolam, 541
amfonelic acid, 623
6-aminomethyl-3-methyl-44- 1,2,4-benzothiadiazine-1,1-dioxide, 667
amitriptylene, 243
amphetamine, 9, 59
*d*-amphetamine, 227, 305, 313, 519, 585, 675, 705, 959
(+)-amphetamine, 1
apomorphine, 163, 201, 291, 317, 411, 593, 605, 717, 807, 871, 941
atropine, 381, 515, 547
baclofen, 405, 593, 657
barbital, 179
bicuculline, 405, 751
BM123, 337
bupropion, 243
buspirone, 269, 317, 567
butylscopolamine, 405
BW 501C67, 475
caffeine, 579, 927
carbachol, 169, 209
carbamazepine, 153
$\beta$-CCE, 767
CGS 8216, 375, 767
CGS 9896, 249
CGS 10746B, 817
charybdotoxin, 187
chloramphenicol, 933

p-chloroamphetamine, 135
chlordiazepoxide, 249, 313, 371, 959
l(m-chlorophenyl) piperazine, 345
m-chlorophenylpiperazine, 305, 567
chlorpromazine, 941, 953, 959
cimetidine, 107
clenbuterol, 807
clomipramine, 103, 807
clonazepam, 153
clonidine, 33, 87
clozapine, 519
cocaine, 327, 387, 623, 877
cycloheximide, 405
cyproheptadine, 81, 345
DALA, 825
2-deoxyglucose, 481
desipramine, 153, 243, 807
diazepam, 15, 153, 541, 597, 693, 709, 733, 959
5,6-dihydroxytryptamine, 135
diisopropylfluorophosphate, 15
1-(2,5-dimethoxyphenyl- 4-iodo)-2-aminopropane, 305
diphenylhydantoin, 153
DL-2-amino-7-phosphonoheptanoic acid, 153
DMCM, 249
domperidone, 69, 201
doxepin, 81
ethanol, 129, 163, 179, 215, 375, 597, 617, 667, 733, 751, 757, 761, 767, 877, 893, 909, 945, 949
ethosuximide, 153
etomidate, 153
fenfluramine, 97, 305, 585
d-fenfluramine, 773
FG 7142, 751, 761, 767
flumazenil, 733, 761
flunarizine, 153
fluoxetine, 475
fluphenazine, 941
flurazepam, 453
gepirone, 269
haloperidol, 201, 317, 515, 519, 817, 861, 941
hemicholinium-3, 547
histidine, 81
8-hydroxy-2(di-n-propylamino) tetralin, 305
6-hydroxydopamine, 357, 605
5-hydroxytryptamine, 855
$^{14}$C-5-hydroxytryptamine, 135
ICI-154,129, 43
imipramine, 97, 807
ketamine, 153
ketanserin, 641, 899
levorphanol, 43
lithium chloride, 909
lorazepam, 937
loxapine, 953
LY53857, 475
marihuana, 649
MDE, 817
MDMA, 239, 817
mephenytoin, 233, 787
meprobamate, 153
3-mercaptopropionic acid, 453
metergoline, 475
methamphetamine, 9, 411
methionine sulfoximine, 797
5-methoxy-N,N-dimethyltryptamine, 839
5-methoxy-N,N-dimethyltryptamine hydrogen oxalate, 305
methsuximide, 787
N-methyl-D-aspartate, 279
methylphenidate, 675
methysergide, 27, 899
metoclopramide, 941
morphine, 63, 123, 193, 351, 393, 397, 431, 439, 561, 641, 825, 855, 893, 933, 959
MR 2034, 825
muscimol, 15, 405
naloxone, 43, 129, 371, 393, 397, 481, 683, 709, 791
naltrexone, 33, 63
nicotine, 265, 617, 713
nomifensine, 243
$^{3}$H-noradrenalin, 135
norepinephrine, 209
norfenfluramine, 305, 817
8-OH-DPAT, 567
oxotremorine, 169, 175, 345
para-chloroamphetamine, 499
parachlorophenylalanine, 509, 899
PD-117302, 425, 899
pentobarbital, 179, 249, 397, 459, 597, 667, 693, 709, 959
pentylenetetrazole, 249, 751, 867
phencyclidine, 279, 927
phencyclidine hydrochloride, 893
phenobarbital, 153, 693
phenobarbitone, 733
phenoxybenzamine, 87, 515
phentolamine, 27
phenylephrine, 87
phenylpropanolamine, 721
physostigmine, 405, 627, 633
picrotoxin, 405, 709
pimozide, 69, 779, 845
pirenperone, 305, 641, 817
PMA, 9
PMMA, 9
prazosin, 573, 899
promethazine, 81
propranolol, 515, 573
purine, 579
pyridostigmine, 381
quinpirole, 1
quipazine, 941
ritanserin, 475, 899
RO 15-1788, 101, 249, 375
RO 15-3505, 751, 761
RO 15-4513, 375, 733, 751, 757, 761, 767, 945
RO 17-1812, 761
sabeluzole, 153
SCH 23390, 941
scopolamine, 175, 405, 547, 633
secobarbital, 459
serotonin, 773
(±)SKF-10,047, 43
SKF 38393, 1
SL 75 102, 249
sodium valproate, 153
soman, 633
sulpiride, 953
sultopride, 941
taurine, 411, 417, 667
temazepam, 611
Δ-9-tetrahydrocannabinol, 365, 893
TFMPP, 37, 53
THIP, 657
thioridazine, 519, 941
thiothixine, 953
1-(m-trifluoromethylphenyl) piperazine, 305
U-50,488, 43, 899
urethane, 397
xylamidine, 475
yohimbine, 89, 321
zimelidine, 243
ZK 93426, 761
Drug addiction model, 605
  classical conditioning
  lesions, 6-hydroxydopamine
  rotational behavior
Drug-admixed food, 123
  morphine
  morphine dependence
Drug comparisons
  γ-aminobutyric acid, 411
  apomorphine, 201
  caudate spindle, 411
  domperidone, 201
  haloperidol, 201
  penile reflexes, 201
  taurine, 411
Drug conditioning, 579
  caffeine
  conditioned taste aversion
Drug discrimination
  benzodiazepine receptor, 249
  CGS 9896, 249
  MDMA, 239, 817
  norfenfluramine, 305
  rapid training method, 239
  serotonergic-dopaminergic mediation, 817
  serotonin mediation, 305
  stimulus antagonism, 249
Drug interactions
  antinociception, 641
  anxiety, 761
  benzodiazepine receptor, 733
  benzodiazepine receptor ligands, 761
  cardiovascular effects, 877
  CGS 8216, 375
  cocaine, 877
  diazepam, 597
  dopamine mechanisms, 593
  ethanol, 375, 597, 733, 761, 877
  ethanol tolerance, 617
  exploratory behavior, 593, 761
  GABA mechanisms, 593
  human studies, male, 877
  hypothermia, 617
  instrumental behaviors, 597
  ketanserin, 641
  locomotor activity, 761
  morphine, 641
  nicotine, 617
  partial inverse agonist, 733
  pentobarbital, 597
  pirenperone, 641
  RO 15-1788, 375, 597
  RO 15-4513, 375, 597, 733
  selective breeding, 667
  schedule-controlled responding, 375
  sleep time, ethanol induced, 667
  tail-flick latency, 641
  taurine, 667
Drug/peptide comparisons, 439
  [D-Arg$^{2}$]-dermorphin
  morphine
  route of administration

Eating, 825
  cannula-mapping
  opioid antagonists
Enantiomers, 475
  fluoxetine
  food intake
  serotonin antagonists
β-Endorphin, 75
  cholesterol
  cingulotomy
  corticosterone
  plasma
  stress
  triglycerides
Ethanol
  alcohol-preferring/alcohol-nonpreferring rat comparisons, 215
  anticonvulsant effects, 751
  anxiety, 761
  apomorphine, 163
  attenuation, 909
  barbital, 179
  benzodiazepine/GABA receptor complex, 751
  benzodiazepine receptor, 733
  benzodiazepine receptor ligands, 761
  cardiovascular effects, 877
  CGS 8216, 375
  chronic treatment, 179
  cocaine, 877
  conditioned emotional response, 949
  conditioned taste aversion, 909
  conflict test, 757
  cross attenuation, 909
  cross tolerance, 179
  diazepam, 597
  drug interactions, 375, 597, 733, 761, 877
  ethanol aversion, 215
  ethanol intake, 949
  exploration, 761
  food intake, 893
  GABA receptor complex, 767
  human studies, male, 877
  ionizing radiation, 909
  instrumental behaviors, 597
  lethality, 945
  lithium chloride, 909
  locomotor activity, 761
  morphine, 893
  motility, 163
  naloxone, 129
  partial inverse agonist, 733
  pentobarbital, 179, 597
  phencyclidine hydrochloride, 893
  reaction time, 757
  RO 15-1788, 375, 597
  RO 15-4513, 375, 597, 733, 751, 757, 767, 945
  schedule-controlled responding, 375
  strain differences, 129
  sucrose-fading procedure, 949
  Δ-9-tetrahydrocannabinol, 893
  Tyr-MIF-1, 129
  volitional drinking, 129
  withdrawal, 163
Ethanol aversion, 215
  alcohol-preferring/alcohol-nonpreferring rat comparisons
  ethanol
Ethanol intake, 949
  Conditioned Emotional Response
  ethanol
  sucrose-fading procedure
Ethanol tolerance, 617
  drug interaction
  hypothermia
  nicotine
Experimental diabetes, 807
  β-adrenoceptors
  tricyclics
Exploration, 761
  anxiety
  benzodiazepine receptor ligands
  drug interactions
  ethanol
  locomotor activity
Exploratory behavior
  dopamine mechanisms, 593
  drug interaction, 593
  GABA mechanisms, 593
  male/female comparisons, 63
  morphine, 63
  naltrexone, 63
  neonatal treatment, 63
  sexual behavior, 63
Exponential data-analysis, 803
  passive-avoidance behavior

Fat intake
  carbohydrate, 773
  d-fenfluramine, 773
  hyperphagia, diet-induced, 773
  peripheral administration, 113
  serotonin, 113, 773
Fenfluramine
  d-amphetamine, 585
  baboons, 585
  food intake, 97, 585
  imipramine, 97
  locomotor activity, 97
  long-term treatment, 97
d-Fenfluramine, 773
  carbohydrate
  fat intake
  hyperphagia, diet-induced
  serotonin
Feeding
  aggression, 43
  analgesia, 43
  anorexia, 209
  carbachol, 209
  hypothalamus, 209
  locomotor activity, 43
  mice, male, 43
  norepinephrine, 209
  opiate agonists, 43
  opiate antagonists, 43
  rats, tumor bearing, 209
Feeding behavior
  antihistamines, 81
  PD-117302, 425
  strain differences, 425
Filter pad validation, 905
  human studies, males
  plasma nicotine
  quantified smoke delivery
Fluid consumption, 313
  anxiety
  chlordiazepoxide
  neophobia
Fluorophotometric assay, 287
  high performance liquid chromatography with electrochemical detection
  urinary catecholamines
Fluoxetine, 475
  enantiomers
  food intake
  serotonin antagonists
Flurazepam, 453
  anesthetic effects
  anticonvulsant effects
  hypothermic effects
  selective breeding
Food deprivation, 487
  food maze performance
  plasma hormone levels
  water maze performance
Food intake
  d-amphetamine, 585
  baboons, 585
  body weight, 533
  buspirone, 567
  cats, 297
  m-chlorophenylpiperazine, 567
  cholecystokinin, 297
  doves, 533
  enantiomers, 475
  ethanol, 893
  fenfluramine, 97, 585
  fluoxetine, 475
  growth hormone, 533
  human satietin, 21
  imipramine, 97
  locomotor activity, 97, 567
  long-term treatment, 97
  morphine, 893
  8-OH-DPAT, 567
  phencyclidine hydrochloride, 893
  prolactin, 533
  route of administration, 21
  serotonin antagonists, 475
  sex differences, 533
  strain differences, 567
  structure-activity relationship, 297
  Δ-9-tetrahydrocannabinol, 893
  water intake, 21
Food maze performance, 487
  food deprivation
  plasma hormone levels
  water maze performance
Food reward, 861
  haloperidol
  neuroleptics
  positive reinforcement
Food selection, 149
  human studies, males
  tryptophan
Formalin test, 855
  analgesia
  5-hydroxytryptamine
  morphine
Freund's complete adjuvant, 445
  hindpaw
  inflammation
  locomotor behavior
  nociceptive thresholds

GABAergic blockade, 193
  aversion
  medial hypothalamus

morphine
periaqueductal gray
GABAergic neuronal system, 405
amnesia
cholinergic neuronal system
cycloheximide
GABA mechanisms, 593
dopamine mechanisms
drug interaction
exploratory behavior
GABA receptor complex, 767
ethanol
RO 15-4513
Galanthamine, 141
lesions, nucleus basalis magnocellularis
spatial memory
Gastric ulceration, 69
anorexia cachexia
domperidone
pimozide
Genital grooming, 717
apomorphine
luteinizing hormone releasing hormone
yawning
Gepirone, 269
buspirone
rats, wild
taming
Gonadal hormones, naltrexone effects, 683
monkeys
pituitary hormones, naltrexone effects
sex differences
Gonadotropin-releasing hormone, 725
rats, pregnant
sexual behavior, postpartum
Growth hormone, 533
body weight
doves
food intake
prolactin
sex differences

Haloperidol
apomorphine, 201
domperidone, 201
drug comparisons, 201
food reward, 861
neuroleptics, 861
penile reflexes, 201
positive reinforcement, 861
Hamsters, 885
aging
hippocampus
hypoactivity
obesity
serotonin
Handling habituation, 541
acute treatment
anxiety
avoidance acquisition
benzodiazepines
chronic treatment
Head-twitch response, 941
dopaminergic supersensitivity
hypermotility
neuroleptics
stereotyped behavior
Heart rate, 561
morphine
sensitivity
tolerance
Hedonic effects, 779
motor effects
operant behavior
pimozide
High performance liquid chromatography with electrochemical detection, 287
fluorophotometric assay
urinary catecholamines
Hindpaw, 445
Freund's complete adjuvant
inflammation
locomotor behavior
nociceptive thresholds
Hippocampus, 885
aging
hamsters
hypoactivity
obesity
serotonin
Hormone
corticosterone, 75
estrogen, 573
gonadotropin-releasing hormone, 725
growth hormone, 533
pregnanes, 919
progesterone, 919
prolactin, 533
Housing, 59
amphetamine
intravenous self-administration
5-HT antagonists, 899
kappa agonists
locomotor activity
5-$HT_{1B}$ receptors, 53
TFMPP
Human satietin, 21
food intake
route of administration
water intake
Human studies
alcohol, 649
behavioral effects, 649
blood pressure, 387
cardiovascular activity, 387
cocaine, 387
comparison profiles, 649
marijuana, 649
subjective effects, 649
task performance, 387
Human studies, males
cardiovascular effects, 877
cocaine, 877
drug interactions, 877
ethanol, 877
filter pad validation, 905
food selection, 149
plasma nicotine, 905
quantified smoke delivery, 905
tryptophan, 149
Human studies, smokers, 93
carbon monoxide
cigarettes
6-Hydroxydopamine, 357
maze learning
motor activity
neonatal administration
5-Hydroxytryptamine, 855
analgesia
formalin test
morphine
Hypermotility, 941
dopaminergic supersensitivity
head-twitch response
neuroleptics
stereotyped behavior
Hyperphagia, diazepam-induced, 709
hyperphagia, pentobarbital-induced
naloxone
picrotoxin
rats, nondeprived
Hyperphagia, diet-induced, 773
carbohydrate
fat intake
d-fenfluramine
serotonin
Hyperphagia, pentobarbital-induced, 709
hyperphagia, diazepam-induced
naloxone
picrotoxin
rats, nondeprived
Hypoactivity, 885
aging
hamsters
hippocampus
obesity
serotonin
Hypomotility, 291
apomorphine
conditioned avoidance
luteinizing hormone releasing hormone
spontaneous motor activity
Hypothalamus, 209
anorexia
carbachol
feeding
norepinephrine
rats, tumor-bearing
Hypothermia
drug interaction, 617
ethanol tolerance, 617
methionine sulfoximine, 797
nicotine, 617
Hypothermic effects, 453
anesthetic effects
anticonvulsant effects
flurazepam
selective breeding

Imipramine, 97
fenfluramine
food intake
locomotor activity
long-term treatment
Inflammation, 445
Freund's complete adjuvant
hindpaw
locomotor behavior
nociceptive thresholds
Insomnia, 509
parachlorophenylalanine
ponto-geniculo-occipital waves
Instrumental behaviors, 597
diazepam
drug interactions
ethanol
pentobarbital
Ro 15-1788
Ro 15-4513
Interactive effects, 927
behavioral dependence

caffeine
monkeys
phencyclidine
Intermittent administration, 871
apomorphine
locomotor activity
stereotypy
Intracranial injections, 493
angiotensin II
drinking
tachykinins
Intracranial self-administration, 243
antidepressant drugs
long-term administration
Intrastriatal injection, 153
anticonvulsants
barrel rotation
intrastriatal injection
Intrathecal administration, 27
analgesia
cold water swim
differential effects
methysergide
phentolamine
Intravenous self-administration
amfonelic acid, 623
amphetamine, 59
cocaine, 623
housing, 59
In vivo, 327
cocaine
computer simulation
dopamine uptake/release
Ionizing radiation, 909
attenuation
conditioned taste aversion
cross-attenuation
ethanol
lithium chloride

Kappa agonists, 899
5-HT antagonists
locomotor activity
Ketanserin, 641
antinociception
drug interactions
morphine
pirenperone
tail-flick latency
Kindling, 867
pentylenetetrazol

Lateral hypothalamus, 547
brainstem
cholinergic antagonists
self-stimulation
ventral tegmentum
Lateral ventricle
carbachol, 169
oxotremorine, 169, 175
preoptic area, 169, 175
rats, experienced males, 169
rats, males, 175
scopolamine, 175
sexual behavior, 169, 175
Lesions, 6-hydroxydopamine
caudate spindle, 417
classical conditioning, 605
dopamine receptors, 417
drug addiction model, 605
rotational behavior, 605
taurine, 417
Lesions, nucleus basalis magnocellularis, 141
galanthamine
spatial memory
Lethality, 945
ethanol
RO 15-4513
Lithium chloride, 909
attenuation
conditioned taste aversion
cross-attenuation
ethanol
ionizing radiation
Locomotor activity
aggression, 43
d-amphetamine, 675
analgesia, 43
anxiety, 761
apomorphine, 871
BALB/cByJ mice, 675
benzodiazepine receptor ligands, 761
buspirone, 567
chlordiazepoxide, 371
m-chlorophenylpiperazine, 567
chronic administration, 675
drug interactions, 761
ethanol, 761
exploration, 761
feeding, 43
fenfluramine, 97
food intake, 97, 567
5-HT antagonists, 899
imipramine, 97
intermittent administration, 871
kappa agonists, 899
long-term treatment, 97
methylphenidate, 675
mice, male, 43
naloxone, 371
8-OH-DPAT, 567
opiate agonists, 43
opiate antagonists, 43
opioid mechanisms, 371
stereotypy, 871
strain differences, 567
Locomotor behavior, 445
Freund's complete adjuvant
hindpaw
inflammation
nociceptive thresholds
Long-term administration, 243
antidepressant drugs
intracranial self-administration
Long-term treatment, 97
fenfluramine
food intake
imipramine
locomotor activity
Lorazepam, 937
sensitization
tolerance
withdrawal
Lordosis, 573
adrenergic receptor antagonists
luteinizing hormone-releasing hormone
sexual experience
Lordosis stimulation, 919
pregnanes
progesterone metabolism
progesterone receptors
Lumbosacral injection, 657
γ-aminobutyric acid antagonists
penile reflexes
rats, male
sexual behavior
Luteinizing hormone releasing hormone
adrenergic receptor antagonists, 573
apomorphine, 291, 717
conditioned avoidance, 291
genital grooming, 717
hypomotility, 291
lordosis, 573
sexual experience, 573
spontaneous motor activity, 291
yawning, 717

Male/female comparisons, 63
exploratory behavior
morphine
naltrexone
neonatal treatment
Marijuana, 649
behavioral effects
comparison profiles
human studies
subjective effects
Maze learning, 357
6-hydroxydopamine
motor activity
neonatal administration
MDMA
drug discrimination, 239, 817
rapid training method, 239
serotonergic-dopaminergic mediation, 817
Medial hypothalamus, 193
aversion
GABAergic blockade
morphine
periaqueductal gray
Mephenytoin
methsuximide, 787
pigeons, 233, 787
reaction time, 787
schedule-controlled responding, 233
Methamphetamine, 9
behavioral investigation
PMMA
Methionine sulfoximine, 797
hypothermia
Method, 287
fluorophotometric assay
high performance liquid chromatography with electrochemical detection
Methsuximide, 787
mephenytoin
pigeons
reaction time
N-Methyl-D-aspartate, 279
discrimination studies
phencyclidine
Methylphenidate, 675
d-amphetamine
BALB/cByJ mice
chronic administration
locomotor activity
Methysergide, 27

analgesia
cold water swim
differential effects
intrathecal administration
phentolamine
Mice, male, 43
aggression
analgesia
feeding
locomotor activity
opiate agonists
opiate antagonists
Midbrain periaqueductal grey, 791
aggression
cats
naloxone
Monetary reinforcement, 227
*d*-amphetamine
concurrent schedule
social interaction
time allocation
Monkeys
atropine, 381
behavioral dependence, 927
caffeine, 927
cardiac response, 381
gonadal hormones, naltrexone effects, 683
interactive effects, 927
opiate/adrenergic receptor blockade, 223
parasympathetic activity, 381
phencyclidine, 927
pituitary hormones, naltrexone effects, 683
pyridostigmine, 381
sex differences, 683
vocalization, 223
Morphine
amniotic fluid, 351
analgesia, 351, 855
antinociception, 641
aversion, 193
chloramphenicol, 933
[D-Arg$^2$]-dermorphin, 439
dose-dependent effects, 351
drug-admixed food, 123
drug interactions, 641
drug/peptide comparisons, 439
ethanol, 893
exploratory behavior, 63
food intake, 893
formalin test, 855
GABAergic blockade, 193
heart rate, 561
5-hydroxytryptamine, 855
ketanserin, 641
male/female comparisons, 63
medial hypothalamus, 193
morphine dependence, 123
naloxone, 393
naltrexone, 63
neonatal rat, 431
neonatal treatment, 63
opiate tolerance, 431
opiate withdrawal, 431
penile reflexes, 393
periaqueductal gray, 139
phencyclidine hydrochloride, 893
pirenperone, 641
placenta, 351
route of administration, 439
self-stimulation, 933
seminal emission, 393
sensitivity, 561
sexual behavior, 63
tail-flick latency, 351, 641
Δ-9-tetrahydrocannabinol, 893
tolerance, 561
Morphine dependence, 123
drug-admixed food
morphine
Motility, 163
apomorphine
ethanol
withdrawal
Motor activity, 357
6-hydroxydopamine
maze learning
neonatal administration
Motor effects, 779
hedonic effects
operant behavior
pimozide
Motor recovery, 187
charybdotoxin
spinal cord injury

Naloxone
aggression, 791
cats, 791
cerebral metabolism, 481
chlordiazepoxide, 371
2-deoxyglucose, 481
ethanol, 129
hyperphagia, diazepam-induced, 709
hyperphagia, pentobarbital-induced, 709
locomotor activity, 371
midbrain periaqueductal grey, 791
morphine, 393
opioid antagonists, 481
opioid mechanisms, 371
penile reflexes, 393
picrotoxin, 709
rats, nondeprived, 709
seminal emission, 393
strain differences, 129
Tyr-MIF-1, 129
volitional drinking, 129
Naltrexone
$\alpha_2$-adrenoceptors, 33
chronic stress, 33
clonidine, 33
exploratory behavior, 63
male/female comparisons, 63
morphine, 63
neonatal treatment, 63
sexual behavior, 63
Neonatal administration
aggression, shock-induced, 103
animal depression model, 103
clomipramine, 103
6-hydroxydopamine, 357
maze learning, 357
motor activity, 357
Neonatal rat, 431
morphine
opiate tolerance
opiate withdrawal
Neonatal treatment, 63
exploratory behavior
male/female comparisons
morphine
naltrexone
sexual behavior
Neophobia, 313
anxiety
chlordiazepoxide
fluid consumption
Neurokinin-$\alpha$
behavioral activation
dopamine
ventral tegmental area
Neuroleptics
delayed matching-to-sample, 953
differential effects, 953
dopaminergic supersensitivity, 941
food reward, 861
head-twitch response, 941
haloperidol, 861
hypermotility, 941
pigeons, 953
positive reinforcement, 861
stereotyped behavior, 941
Neurotransmitter turnover rates, 523
punishment
Nicotine
acute exposure, 265
analgesia, 265
chronic exposure, 265
drug interaction, 617
ethanol tolerance, 617
hypothermia, 617
restraint stress, 265
sustained release, 713
tolerance development, 265
Nociceptive thresholds, 445
Freund's complete adjuvant
hindpaw
inflammation
locomotor behavior
Nonopioid analgesia, 107
cimetidine
cold-water swims
opioid analgesia
Norepinephrine, 209
anorexia
carbachol
feeding
hypothalamus
rats, tumor bearing
Norfenfluramine, 305
drug discrimination
serotonin mediation

Obesity, 885
aging
hamsters
hippocampus
hypoactivity
serotonin
Offspring effects, 839
brain development
prenatal stress
serotonergic system
Offspring lethality, 365
delta-9-tetrahydrocannabinol
DNA development
postnatal brain growth
prenatal exposure
protein development

RNA development
8-OH-DPAT, 567
buspirone
M-chlorophenylpiperazine
food intake
locomotor activity
strain differences
Operant behavior, 779
hedonic effects
motor effects
pimozide
Opiate/adrenergic receptor blockade, 223
monkeys
vocalization
Opiate agonists, 43
aggression
analgesia
feeding
locomotor activity
mice, male
opiate antagonists
Opiate antagonists, 43
aggression
analgesia
feeding
locomotor activity
mice, male
opiate agonists
Opiates, 397
analgesia
anesthesia
differential effects
tail flick latency
Opiate tolerance, 431
morphine
neonatal rat
opiate withdrawal
Opiate withdrawal, 431
morphine
neonatal rat
opiate tolerance
Opioid agonists, 825
cannula-mapping
eating
Opioid analgesia, 107
cimetidine
cold-water swims
nonopioid analgesia
Opioid antagonists, 481
cerebral metabolism
2-deoxyglucose
naloxone
Opioid mechanisms, 371
chlordiazepoxide, 371
locomotor activity
naloxone
Opposing effects, 1
conditioned place preference
conditioned taste aversion
dopamine agonists
Oral administration, 467
aluminum
chronic administration
passive avoidance
Oxotremorine
carbachol, 169
lateral ventricle, 169, 175
preoptic area, 169, 175
rats, experienced males
rats, males, 175
scopolamine, 175
sexual behavior, 169, 175
Parachlorophenylalanine, 509
insomnia
ponto-geniculo-occipital waves
Parasympathetic activity, 381
atropine
cardiac response
monkeys
pyridostigmine
Partial inverse agonist, 733
benzodiazepine receptor
drug interactions
ethanol
RO 15-4513
Passive avoidance
aging, 611
aluminum, 467
chronic administration, 467
exponential data-analysis, 803
oral administration, 467
serotonergic system, 499
sex differences, 499
temazepam, 611
PD-117302, 425
feeding behavior
strain differences
Penile reflexes
γ-aminobutyric acid antagonists, 657
apomorphine, 201
domperidone, 201
drug comparisons, 201
haloperidol, 201
lumbosacral injection, 657
morphine, 393
naloxone, 393
rats, male, 657
seminal emission, 393
sexual behavior, 657
Pentobarbital
aminooxyacetic acid, 693
anticonflict effects, 693
barbital, 179
chronic administration, 459
chronic treatment, 179
cross-tolerance, 179
diazepam, 597, 693
drug interactions, 597
ethanol, 179, 597
instrumental behaviors, 597
phenobarbital, 693
pigeon/rat comparisons, 459
Ro 15-1788, 597
Ro 15-4513, 597
secobarbital, 459
tolerance, 459
Pentylenetetrazol, 867
kindling
Peptide
adrenocorticotropic hormone, 515
angiotensin II, 493, 813
cholecystokinin, 297
[D-Arg$^2$]-dermorphin, 439
eledoisin, 493
β-endorphin, 75
kassinin, 493
luteinizing hormone releasing hormone, 291, 573, 717
neurokinin-α, 255
Sar-1 Thr-8 angiotensin II, 813
satietin, 21
substance P, 255, 493
Tyr-MIF-1, 129
Performance, 845
current intensity
pimozide
reward
self-stimulation
Periaqueductal gray, 193
aversion
GABAergic blockade
medial hypothalamus
morphine
Peripheral administration, 113
fat intake
serotonin
Phencyclidine, 927
behavioral dependence
caffeine
discrimination studies, 279
interactive effects, 927
N-methyl-D-aspartate, 279
monkeys, 927
Phencyclidine hydrochloride, 893
delta-9-tetrahydrocannabinol
ethanol
food intake
morphine
Phenobarbital, 693
aminooxyacetic acid
anticonflict effects
diazepam
pentobarbital
Phentolamine, 27
analgesia
cold water swim
differential effects
intrathecal administration
methysergide
Phenylpropanolamine, 721
diet selection
Physostigmine, 633
continuous administration, 627, 633
scopolamine
soman
soman activity
toxicity study, 627
Picrotoxin, 709
hyperphagia, diazepam-induced
hyperphagia, pentobarbital-induced
naloxone
rats, nondeprived
Pigeon/rat comparisons, 459
chronic administration
pentobarbital
secobarbital
tolerance
Pigeons
delayed matching-to-sample, 953
differential effects, 953
mephenytoin, 233, 787
methsuximide, 787
neuroleptics, 953
reaction time, 787
schedule-controlled responding, 233
Pimozide
anorexia cachexia, 69
current intensity, 845
domperidone, 69
gastric ulceration, 69
hedonic effects, 779
motor effects, 779
operant behavior, 779
performance, 845
reward, 845
self-stimulation, 845

D-Pipecolic acid, 833
prolyl-leucyl- glycinamide
retrograde amnesia
Pirenperone, 641
antinociception
drug interactions
ketanserin
morphine
tail-flick latency
Pituitary hormones, naltrexone effects, 683
gonadal hormones, naltrexone effects
monkeys
sex differences
Placenta, 351
amniotic fluid
analgesia
dose-dependent effects
morphine
tail-flick latency
Plasma, 75
cholesterol
cingulotomy
corticosterone
β-endorphin
stress
triglycerides
Plasma hormone levels, 487
food deprivation
food maze performance
water maze performance
Plasma nicotine, 905
filter pad validation
human studies, male
quantified smoke delivery
PMMA, 9
behavioral investigation
methamphetamine
Ponto-geniculo-occipital waves, 509
insomnia
parachlorophenylalanine
Positive reinforcement, 861
food reward
haloperidol
neuroleptics
Postnatal brain growth, 365
delta-9-tetrahydrocannabinol
DNA development
offspring lethality
prenatal exposure
protein development
RNA development
[$^3$H]-Prazosin binding, 505
aging
cortex
Pregnanes, 919
lordosis stimulation
progesterone metabolism
progesterone receptors
Prenatal exposure, 365
delta-9-tetrahydrocannabinol
DNA development
offspring
postnatal brain growth
protein development
RNA development
Prenatal stress, 839
brain development
offspring effects
serotonergic system
Preoptic area
carbachol, 169
lateral ventricle, 169, 175
oxotremorine, 169, 175
rats, experienced males, 169
rats, males, 175
scopolamine, 175
sexual behavior, 169, 175
Progesterone metabolism, 919
lordosis stimulation
pregnanes
progesterone receptors
Progesterone receptors, 919
lordosis stimulation
pregnanes
progesterone metabolism
Prolactin, 533
body weight
doves
food intake
growth hormone
sex differences
Prolyl-leucyl-glycinamide, 833
D-pipecolic acid
retrograde amnesia
Protein development, 365
delta-9-tetrahydrocannabinol
DNA development
offspring
postnatal brain growth
prenatal exposure
RNA development
Psychopharmacological profile, 37
TFMPP
Punishment, 523
neurotransmitter turnover rates
Pyridostigmine, 381
atropine
cardiac response
monkeys
parasympathetic response

Quantified smoke delivery, 905
filter pad validation
human studies, male
plasma nicotine
Quinolinic acid, 153
anticonvulsants
barrel rotation
intrastriatal injection

Rapid training method, 239
drug discrimination
MDMA
Rats, experienced males, 169
carbachol
lateral ventricle
oxotremorine
preoptic area
sexual behavior
Rats, male
γ-aminobutyric acid antagonists, 657
lateral ventricle, 175
lumbosacral injection, 657
oxotremorine, 175
penile reflexes, 657
preoptic area, 175
scopolamine, 175
sexual behavior, 175, 657
Rats, nondeprived, 709
hyperphagia, diazepam-induced
hyperphagia, pentobarbital-induced
naloxone
picrotoxin
rats, nondeprived
Rats, pregnant, 725
gonadotropin-releasing hormone
sexual behavior, postpartum
Rats, tumor bearing, 209
anorexia
carbachol
feeding
hypothalamus
norepinephrine
Rats, wild, 269
buspirone
gepirone
taming
Reaction time
conflict test, 757
ethanol, 757
mephenytoin, 787
methsuximide, 787
pigeons, 787
RO 15-4513, 757
Receptor blockers, 515
active avoidance reflex extinction
adrenocorticotropic hormone
Restraint stress, 265
acute exposure
analgesia
chronic exposure
nicotine
tolerance development
Retrograde amnesia, 833
D-pipecolic acid
prolyl-leucyl-glycinamide
Reward, 845
current intensity
performance
pimozide
self-stimulation
RNA development, 365
delta-9-tetrahydrocannabinol
DNA development
offspring
postnatal exposure
prenatal brain growth
protein development
Ro 15-1788
CGS 8216, 375
diazepam, 597
drug interactions, 375, 597
ethanol, 597
instrumental behaviors, 597
pentobarbital, 597
Ro 15-4513, 375, 597
schedule-controlled responding, 375
Ro 15-4513
anticonvulsant effects, 751
benzodiazepine/GABA receptor complex, 751
benzodiazepine receptors, 733
CGS 8216, 375
conflict test, 757
diazepam, 597
drug interactions, 375, 597, 733
ethanol, 375, 597, 733, 751, 757, 767, 945
GABA receptor complex, 767
instrumental behaviors, 597
lethality, 945

partial inverse agonist, 733
pentobarbital, 597
reaction time, 757
Ro 15-1788, 375, 597
schedule-controlled responding, 375
Rotational behavior, 605
classical conditioning
drug addiction model
lesions, 6-hydroxydopamine
Route of administration
[D-Arg$^2$]-dermorphin, 439
colchicine, 579
drug/peptide comparisons, 439
food intake, 21
human satietin, 21
micturition, 579
morphine, 439
water intake, 21

Sar-1 Thr-8 angiotensin II, 813
angiotensin II
alcohol intake
Scopolamine
continuous administration, 633
lateral ventricle, 175
oxotremorine, 175
physostigmine, 633
preoptic area, 175
rats, males, 175
sexual behavior, 175
soman, 633
soman activity, 633
Schedule-controlled responding
CGS 8216, 375
drug interactions, 375
ethanol, 375
mephenytoin, 233
pigeon, 233
Ro 15-1788, 375
Ro 15-4513, 375
Secobarbital, 459
chronic administration
pentobarbital
pigeon/rat comparisons
tolerance
Selective breeding
anesthetic effects, 453
anticonvulsant effects, 453
cholinergic function, 345
drug interaction, 667
flurazepam, 453
hypothermic effects, 453
serotonergic sensitivity, 345
sleep time, ethanol-induced, 667
taurine, 667
Self-stimulation
brainstem, 547
chloramphenicol, 933
cholinergic antagonists, 547
current intensity, 845
lateral hypothalamus, 547
morphine, 933
performance, 845
pimozide, 845
reward, 845
ventral tegmentum, 547
Seminal emission, 393
morphine
naloxone
penile reflexes
Sensitivity, 561
heart rate
morphine
tolerance
Sensitization
amphetamine, 705
circling behavior, 705
lorazepam, 937
tolerance, 937
withdrawal, 937
Serotonergic-dopaminergic mediation, 817
drug discrimination
MDMA
Serotonergic pathways, 135
antinociception
p-chloroamphetamine
Serotonergic sensitivity, 345
cholinergic function
selective breeding
Serotonergic system
brain development, 839
offspring effects, 839
passive avoidance, 499
prenatal stress, 839
sex differences, 499
Serotonin
aging, 885
carbohydrate, 773
fat intake, 113
d-fenfluramine, 773
hamster, 885
hippocampus, 885
hyperphagia, diet-induced, 773
hypoactivity, 885
obesity, 885
peripheral administration, 113
Serotonin antagonists, 475
enantiomers
fluoxetine
food intake
Serotonin mediation, 305
drug discrimination
norfenfluramine
Sex differences
body weight, 533
doves, 533
food intake, 533
gonadal hormones, naltrexone effects, 683
growth hormone, 533
monkeys, 683
passive avoidance, 499
pituitary hormones, naltrexone effects, 683
prolactin, 533
serotonergic system, 499
Sexual behavior
γ-aminobutyric acid antagonists, 657
carbachol, 169
exploratory behavior, 63
lateral ventricle, 169, 175
lumbosacral injection, 657
male/female comparisons, 63
morphine, 63
naltrexone, 63
neonatal treatment, 63
oxotremorine, 169, 175
preoptic area, 169, 175
penile reflexes, 657
rats, experienced males, 169
rats, male, 175, 657
scopolamine, 175
Sexual behavior, postpartum, 725
gonadotropin-releasing hormone
rats, pregnant
Sexual experience, 573
adrenergic receptor antagonists
lordosis
luteinizing hormone-releasing hormone
Sleep time, ethanol-induced, 667
drug interaction
selective breeding
taurine
Social interaction, 227
d-amphetamine
concurrent schedule
monetary reinforcement
time allocation
Soman, 633
continuous administration
physostigmine
scopolamine
soman activity
Soman activity, 633
continuous administration
physostigmine
scopolamine
soman
Spatial memory, 141
galanthamine
lesions, nucleus basalis magnocellularis
Spinal cord injury, 187
charybdotoxin
motor recovery
Spontaneous alternation, 337
avoidance
BM123
Spontaneous motor activity, 291
apomorphine
conditioned avoidance
hypomotility
luteinizing hormone releasing hormone
Stereotyped behavior, 941
dopaminergic supersensitivity
head-twitch response
hypermotility
neuroleptics
Stereotypy
d-amphetamine, 519
apomorphine, 871
atypical antipsychotics, 519
intermittent administration, 871
locomotor activity, 871
Stimulus antagonism, 249
benzodiazepine receptor
CGS 9896
drug discrimination
Strain differences
buspirone, 567
m-chlorophenylpiperazine
ethanol, 129
feeding behavior, 425
food intake, 567
locomotor activity, 567
naloxone, 129
8-OH-DPAT, 567
PD-117302, 425
Tyr-MIF-1, 129
volitional drinking, 129
Stress, 75
cholesterol
cingulotomy
corticosterone

β-endorphin
plasma
triglycerides
Stress ulcer, 317
anxiety
buspirone
dopamine transmitters
Structure-activity relationship, 297
cats
cholecystokinin
food intake
Subjective effects, 649
alcohol
behavioral effects
comparison profiles
human studies
marijuana
Sucrose-fading procedure, 949
Conditioned Emotional Response
ethanol
ethanol intake
Sustained release, 713
nicotine

Tachykinins, 493
angiotensin II
drinking
intracranial injections
Tail-flick latency
amniotic fluid, 351
analgesia, 351, 397
anesthesia, 397
antinociception, 641
differential effects, 397
dose-dependent effects, 351
drug interactions, 641
ketanserin, 641
morphine, 351, 641
opiates, 397
pirenperone, 641
placenta, 351
Taming, 269
buspirone
gepirone
rats, wild
Task performance, 387
blood pressure
cardiovascular activity
cocaine
human studies
Taurine
γ-aminobutyric acid, 411
caudate spindle, 411, 417
dopamine receptors, 417
drug comparisons, 411
drug interaction, 667
lesions, 6-hydroxydopamine, 417
selective breeding, 667
sleep time, ethanol-induced, 667
Temazepam, 611
aging
passive-avoidance response
Δ-9-Tetrahydrocannabinol
DNA development, 365
ethanol, 893
food intake, 893
morphine, 893
offspring lethality, 365
phencyclidine hydrochloride, 893
postnatal brain growth, 365
prenatal exposure, 365
protein development, 365
RNA development, 365
TFMPP
psychopharmacological profile, 37
5-$HT_{1B}$ receptors, 53
Thermoregulatory responses, 699
acute administration
ammonium chloride
creatinine
urea
Thigmotaxis, 959
anxiolytic activity
Time allocation, 227
d-amphetamine
concurrent schedule
monetary reinforcement
social interaction
Tolerance
heart rate, 561
lorazepam, 937
morphine, 561
sensitivity, 561
sensitization, 937
withdrawal, 937
Tolerance development
acute exposure, 265
analgesia, 265
chronic administration, 459
chronic exposure, 265
nicotine, 265
pentobarbital, 459
pigeon/rat comparisons, 459
restraint stress, 265
secobarbital, 459
Toxicity study, 627
continuous administration
physostigmine
Tricyclics, 807
β-adrenoceptors
experimental diabetes
Triglycerides, 75
cholesterol
cingulotomy
corticosterone
β-endorphin
plasma
stress
Tryptophan, 149
food selection
human studies, males
Tyr-MIF-1, 129
ethanol
naloxone
strain differences
volitional drinking

Urea, 699
acute administration
ammonium chloride
creatinine
thermoregulatory responses
Urinary catecholamines, 287
fluorophotometric assay
high performance liquid
chromatography with
electrochemical detection

Ventral tegmental area
behavioral activation, 255
brainstem, 547
cholinergic antagonists, 547
dopamine, 255
lateral hypothalamus, 547
neurokinin-α
self-stimulation, 547
Vocalization, 223
monkeys
opiate/adrenergic receptor blockade
Volitional drinking, 129
ethanol
naloxone
strain differences
Tyr-MIF-1

Water intake, 21
food intake
human satietin
route of administration
Water maze performance, 487
food deprivation
food maze performance
plasma hormone levels
Withdrawal
apomorphine, 163
ethanol, 163
lorazepam, 937
motility, 163
sensitization, 937
tolerance, 937

Yawning, 717
apomorphine
genital grooming
luteinizing hormone releasing hormone
Yohimbine, 321
antiserotonergic properties

# AUTHOR INDEX


Abbott, F. V., 855
Abbott, P., 351
Aihara, H., 411, 417
Allweis, C., 803
Aloyo, V. J., 265
Amit, Z., 59
Anderson, G. H., 149
Archer, T., 357
Asami, T., 709
Asencio, M., 927
Aulakh, C. S., 97, 567

Bado, A., 297
Baláspiri, L., 833
Balázs, M., 515
Band, L. C., 169, 175
Banks, W. A., 397
Barocelli, E., 493
Barr, J. K., 187
Bazzett, T. J., 175, 201
Beninger, R. J., 1
Benitez, R. R., 21
Berg, M., 63
Berge, O.-G., 135
Beshears, J. F., 693
Beyer, C., 573, 919
Bigelow, G. E., 649
Birnbaum, S. G., 381
Bitran, D., 169, 175, 657
Bjørkum, A. A., 135
Blakely, E., 787, 945
Blanchard, D. C., 269
Blundell, J. E., 773
Bobyock, E., 667
Bodnar, R. J., 107
Boix, F., 541
Boja, J. W., 305
Bonetti, E. P., 733
Bonna, R., 885
Boon, P., 499
Booth, R. A., 337
Borer, K. T., 885
Brake, S. C., 365
Brauer, L. H., 927
Bree, M. P., 683
Britton, K. T., 757
Brodie, G., 69
Brown, A. J., 487
Buntin, J. D., 533
Burkard, W. P., 733
Burns, L. H., 255
Byers, K. I., 713

Cadafalch, J., 605
Cancela, L. M., 33
Cao, W., 675
Capriotti, R. M., 387
Carney, J. M., 675
Carroll, M. E., 927
Casas, M., 605
Chaki, K., 439
Chance, W. T., 209
Chatelain, F., 807
Cherian, L., 87
Chernichovsky, D., 803
Chiavarini, M., 493
Clemens, L. G., 169, 175
Co, C., 523
Colasanti, B. K., 867
Commissaris, R. L., 693
Connor, D. J., 467
Copeland, R. L., Jr., 933
Copolov, D. L., 75
Coyle, J. T., 141
Craig, C. R., 867
Cramer, C. P., 431
Crawley, J., 767
Crocker, A. D., 15, 345
Cunningham, C. L., 561
Czachura, J. F., 163

Dall'Olio, R., 941
D'Angelo, P. C., 487
Danysz, W., 357
de Caro, G., 493
de Groot, G., 123
Delaney, D., 233
Dellinger, J. A., 381
Diaz-Veliz, G., 291, 717
Drew, K. L., 705
Dubrasquet, M., 297
Dunlap, K. D., 725
Dushkin, H., 113
Dworkin, S. I., 523
Dwoskin, L. P., 321

Eaton, R. C., 201
Eckel, D. L., 579
Eggleston, T., 487
Eguíbar, J. R., 919
Erickson, C. K., 713
Ettenberg, A., 861

Fanelli, R. J., 481
Fanselow, M. S., 431
Feenstra, M. G. P., 499
Feria, M., 393
Ferko, A. P., 667
Ferre, S., 605
Figge, G. R., 533
File, S. E., 937
Fischer, J. E., 209
Fischman, M. W., 387, 585, 877
Foltin, R. W., 387, 585, 877
Frances, H., 37
Frankenhaeuser, M., 287
Fredriksson, A., 357
Freund, R. K., 453
Froehlich, J. C., 215
Fundytus, M., 959

Gabl, M., 733
Galina, Z. H., 397
Gamagaris, Z., 365
Gandolfi, O., 941
Gayet, J., 797
Gilbert, D. G., 905
Ginefri-Gayet, M., 797
Glennon, R. A., 9
Glick, S. D., 705
Glowa, J. R., 767
Gomez-Marrero, J., 393
Gómora, P., 919
Gonzalez, L. P., 163
González-Mariscal, G., 573, 919
Goodman, N. L., 623
Gordon, C. J., 699
Gotsick, J. E., 871
Gougos, A., 179
Grupp, L. A., 813
Guix, T., 605

Haefely, W. E., 733
Hagen, E. W., 927
Hagler, M., 103
Halas, N. A., 693
Harrell, L. E., 467
Harris, J. C., 223
Hartley, P., 103
Harts, J., 215
Hashimoto-Kitsukawa, A., 411
Hashimoto-Kitsukawa, S., 417
Heinsbroek, R. P. W., 499
Heishman, S. J., 649
Hendrie, C. A., 269
Henke, P. G., 317
Henry, J. L., 27
Herz, A., 445
Higgins, S. T., 227
Hill, A. J., 773
Hill, J. L., 97, 567
Hill, R. G., 425, 899
Hiltunen, A. J., 597
Hjeresen, D. L., 617
Ho, I. K., 627, 633
Hoebel, B. G., 721
Hoffman, D. C., 1
Höglund, U., 593
Höhmann, C. F., 141
Holmbegg, L., 287
Holmes, G. M., 169, 175
Hori, K., 269
Horvitz, J. C., 861
Hoskins, B., 627, 633
Hough, L. B., 107
Hubbell, C. L., 893
Hughes, J., 425, 899
Hui, Y., 893
Hull, E. M., 169, 175, 201
Hunkeler, W., 733
Hunt, W. A., 909
Hutchings, D. E., 365

Impicciatore, M., 493
Ismaiel, A. E.-K. M., 9
Ito, Y., 627, 633
Itoh, K., 405

Jane, F., 605
Järbe, T. U. C., 597
Jasinski, D. R., 481
Jenck, F., 193
Jenden, D. J., 337
Jensen, R. A., 905
Johansson, B., 63
Jope, R. S., 467
Justice, J. B., Jr., 327

Kalant, H., 179
Kameyama, T., 405
Kanarek, R. B., 113
Kant, G. J., 487
Karli, P., 193
Kastin, A. J., 129, 397
Katagi, C., 187
Kavaliers, M., 43
Kawamura, S., 439
Kelley, A. E., 255
Khanna, J. M., 179
Kielb, M., 885
Kisara, K., 439
Klemm, W. R., 87
Kofman, O., 547
Koizumi, Y., 709
Kokkinidis, L., 243
Komiskey, H. L., 611
Koob, G. F., 757
Kors, D., 103
Kovács, G. L., 833
Kristal, M. B., 351

Lanthier, D., 825
Lê, A. D., 179
Lee, J., 909
Leibowitz, S. F., 825
Leidenheimer, N. J., 249
Leighton, G. E., 425, 899
Leipheimer, R. E., 657
Lewin, M., 297
Li, T.-K., 215
Lim, D. K., 627, 633
Lindgren, S., 593
Lister, R. G., 731, 751, 761
Lodge, D., 279
Loeber, J. G., 123
Logan, L., 675
London, E. D., 481
Lorez, H.-P., 733
Lumeng, L., 215
Lundberg, U., 287
Luthman, J., 357

McCarter, B. D., 243
McCloskey, T. C., 693
McEntee, M. A., 387
McQuade, D. B., 657

Mabbutt, P. S., 937
Mana, M. J., 641
Marin, C., 871
Marks, G. A., 509
Marley, R. J., 453
Marrannes, R., 153
Martin, B., 9
Martin, D., 279
Martin, J. R., 733
Martin, P., 807
Martinez, J., 297
Mas, M., 393
Massi, M., 493
Massie, C. A., 953
Massol, J., 807
Mattingly, B. A., 871
Mekarski, J. E., 845
Meliska, C. J., 905
Mello, N. K., 683
Mendel, V. E., 21
Mendelson, J. H., 683
Meyerson, B. J., 63
Milano, W. C., 893
Millan, M. J., 445
Miller, N., 365

Miller, S. A., 657
Miyauchi, T., 523
Moehler, H., 733
Molina, V. A., 33
Montanaro, N., 941
Mora, S., 291, 717
Moran, T. H., 141
Moreau, J. L., 193
Morgan, B., 365
Mousa, S. A., 265
Mundinger, K. L., 611
Murphy, D. L., 97, 567

Nabeshima, T., 405
Naruse, T., 709
Neal, B. S., 321
Neill, D., 103
Newman, J. D., 223
Nicolaysen, L. C., 327
Noda, Y., 405
Nowak, G., 505
Nutt, D. J., 731, 751

Ohnishi, S. T., 187
Okuyama, S., 411, 417
O'Regan, M. H., 579
Orthen-Gambill, N., 81
Osterrieder, W., 733
Overstreet, D. H., 15, 337, 345

Pálos, É., 833
Paul, D., 641
Paul, S. M., 767
Pedrosa, J. J., 387
Pehek, E. A., 169, 175, 201
Pellettiere, V., 233
Pepe, S., 15
Percy, L., 757
Perlanski, E., 813
Peters, D. A. V., 839
Pfaus, J. G., 641
Picker, M. J., 953
Pieri, L., 733
Pihl, R. O., 149
Pinel, J. P. J., 641
Poff, D., 9
Polc, P., 733
Poling, A., 233, 787, 945
Porrino, L. J., 623
Porter, J. H., 779
Pradhan, S. N., 933
Prat, G., 605
Puech, A.-J., 807
Pulvirenti, L., 129

Rabin, B. M., 909
Rahman, A., 611
Ray, A., 317
Rebec, G. V., 519
Recher, H., 75
Reid, L. D., 893
Reid, L. R., 475
Richards, J. G., 733
Richardson, B. C., 381
Robertson, J. A., 107
Robinson, B., 59
Rochford, J., 27
Rodgers, R. J., 269
Rodriguez, M., 297
Roffwarg, H. P., 509
Roncada, P., 941
Rusiniak, K. W., 579

Sachs, B. D., 657
Sadanaga, K. K., 187
Sadeghi, K. G., 949
Sakurada, S., 439
Sakurada, T., 439
Samson, H. H., 949
Sansone, M., 371
Sato, T., 439
Schaffner, R., 733
Schechter, M. D., 53, 239, 249, 305, 817
Schenk, S., 59
Scherschlicht, R., 733
Schlinger, H., 233, 945
Schoch, P., 733
Schwartz, D. H., 721
Schwarz, K. S., 561
Seale, T. W., 675
Sekhuis, V. M., 123
Shaikh, M. B., 791
Sharpe, L. G., 623
Shephard, R. A., 313
Shulz, D., 803
Siegel, A., 791
Silberring, J., 505
Skupny, A., 683
Slangen, J. L., 375
Sleeman, M., 69
Smith, G. C., 69, 75
Smith, J. E., 523
Soubrié, P., 807
Sparber, S. B., 321
Sridaran, R., 725
Stanley, B. G., 825
Starin, S., 787
Steigerwald, E. S., 579
Stein, C., 445
Stewart, R. B., 813
Stewart, T., 627
Stitzer, M. L., 93, 227, 649
Sukul, N. C., 87
Sullivan, R. M., 317
Sundström, E., 357
Sutton, M., 9
Suzdak, P. D., 767
Suzuki, K., 439
Sweeney, J. E., 141
Szabó, G., 833
Szpornyi, L., 833

Teff, K. L., 149
Teiling, A., 357
Telegdy, G., 515, 833
Teruel, A. F., 541
Teskey, G. C., 43
Tetzke, T. A., 21
Thompson, A. C., 351
Thompson, J. T., 201
Threlkeld, P. G., 475
Tobeña, A., 541
Tolliver, G. A., 949
Tourjman, S. V., 149
Treit, D., 959
Trentman, T. L., 397
Tschanz, J. T., 519

Vaccheri, A., 941
van Haaren, F., 499
van de Poll, N. E., 499
van der Laan, J. W., 123
van Lammeren, F. M., 209
Van Loon, G. R., 265
Vetulani, J., 371
Villanueva, H. F., 779
Vogel, G., 103
Volosin, M., 33

Wallis, E., 345
Walovitch, R. C., 481
Warner, R. K., 169, 175
Watanabe, H., 439
Wauquier, A., 153
Wehner, J. M., 453
Weinhold, L. L., 93
Wenger, G. R., 459
Westerling, P., 593
Wild, K. D., 893
Willis, G. L., 69, 75
Wilks, L. J., 937
Wong, D. T., 475
Woudenberg, F., 375
Wozniak, K. M., 97

Yen, M. H., 487
Yeomans, J. S., 547
Yingling, J. E., 93
Young, S. N., 149, 855
Yu, Z. J., 633